Q-omics provides the consensus-scored FAM151B profile across patient tissues and cancer cell-line models. FAM151B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FAM151B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, FAM151B protein abundance shows 21,511 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KICH, and LSCC as cancer lineages where FAM151B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM151B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM151B survival associations across molecular data types. FAM151B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM151B RNA expression–survival associations across cancer types. High FAM151B expression shows unfavorable associations in KICH, LGG and UVM, but favorable associations in HNSC, COAD and ESCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FAM151B RNA expression.
This table summarizes FAM151B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM151B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM151B shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LIHC, BRCA and CHOL. The KICH box plot shows higher FAM151B RNA expression in normal versus tumor tissue (log2 FC = −1.085, t-test p < 0.001).
This table shows molecular features associated with FAM151B in patient tissues and cancer cell lines. In patient samples, FAM151B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM151B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
